Abstract:Delayed cerebral ischemia as a result of cerebral vasospasm is the most common cause of death and disability after aneurysmal subarachnoid hemorrhage (SAH). It leads to death or permanent neurologic deficits in over 17-40% of SAH patients. The initial and main symptom of cerebral vasospasm is diffuse headache and may be accompanied with a slight increase in discomfort from neck stiffness and fever. The clinical diagnosis of cerebral vasospasm is made when the patient experiences an altered level of consciousness or a new focal neurologic deficit. There has been a great progress in identifying the patients at risk, putative mechanisms, and possible treatment options for cerebral vasospasm. However, the problem is by no means solved, mainly due to a limited understanding of the pathologic mechanisms of this complex disease. The iatrogenic factors that can increase the risk of cerebral vasospasm include prolongation of the subarachnoid clot by antifibrinolytic drugs, hypotension, inappropriate treatment of hyponatremia, hypovolemia, hyperthermia and increased intracranial pressure. Nimodipine has been shown to improve neurologic outcome and decrease the incidence of cerebral vasospasm. Triple H therapy is a treatment designed to augment cerebral blood flow for patient with cerebral vasospasm. Hypervolemic hypertension is induced with intravenous volume expansion with crystalloid or colloid to increase cardiac output and raise blood pressure. However, small randomized trials showed no clear benefit. Recently, balloon and chemical angioplasty with superselective intra-arterial injection of vasodilators has emerged as the primary intervention for treating medically refractory ischemia from cerebral vasospasm and in many centers is being used as a first-line treatment or even prophylactically. In addition, promising new treatments for cerebral vasospasm or its ischemic complications include magnesium sulfate, fasudil hydrochloride, tirilazad mesylate, erythropoietin, and induced hypothermia; however, all still need further clinical trials. Newly recognized mediators of cerebral vasospasm after SAH include endothelium-derived mediators, vascular smooth-muscle-derived mediators, proinflammatory mediators involved in blood-brain barrier disruption, cytokines and adhesion molecules, stress-induced gene activation, and platelet-derived growth factors. Moreover, observations in the laboratory have, in many circumstances, matched those of reported small series. Larger, prospective, randomized trials are needed to verify several hypotheses of molecular pathophysiology and clinical treatment regimens.

Effects of a New Magnesium-Rich Artificial Cerebrospinal Fluid on Contractile 5-Hydroxytryptamine and Endothelin Receptors in Rat Cerebral Arteries

Potential risk of artificial cerebrospinal fluid solution without magnesium ion for cerebral irrigation and perfusion in neurosurgical practice

Initial clinical experience of vasodilatory effect of intra-cisternal infusion of magnesium sulfate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage

Magnesium sulfate reverses experimental delayed cerebral vasospasm after subarachnoid hemorrhage in rats

Temporal profile of the effects of intracisternal injection of magnesium sulfate solution on vasodilation of spastic cerebral arteries in the canine SAH model

Optimal cerebrospinal fluid magnesium ion concentration for vasodilatory effect and duration after intracisternal injection of magnesium sulfate solution in a canine subarachnoid hemorrhage model

Effect of intrathecal magnesium sulfate solution injection via a microcatheter in the cisterna magna on cerebral vasospasm in the canine subarachnoid haemorrhage model

Neuroprotective Effects of Magnesium Lithospermate B Against Subarachnoid Hemorrhage in Rats

Safety and efficacy of magnesium-rich artificial cerebrospinal fluid for subarachnoid hemorrhage

Blood-filled Cerebrospinal Fluid-Enhanced Pericyte Microvasculature Contraction in Rat Retina: A Novel in Vitro Study of Subarachnoid Hemorrhage.

Role of Endothelin‑1 and Its Receptors in Cerebral Vasospasm Following Subarachnoid Hemorrhage.

Vascular pathology of large cerebral arteries in experimental subarachnoid hemorrhage: Vasoconstriction, functional CGRP depletion and maintained CGRP sensitivity

Bloody cerebrospinal fluid from patients with subarachnoid hemorrhage alters intracellular calcium regulation in cultured human vascular endothelial cells

Effects of early lumbar cistern drainage of cerebrospinal fluid and combination of edaravone and nimodipine on vasospasm, intracranial pressure, inflammatory factors in traumatic subarachnoid hemorrhage

Changes in arterial myocyte excitability induced by subarachnoid hemorrhage in a rat model

Upregulation of Connexin 40 Mediated by Nitric Oxide Attenuates Cerebral Vasospasm after Subarachnoid Hemorrhage Via the Nitric Oxide-Cyclic Guanosine Monophosphate-Protein Kinase G Pathway.

Changes of Endothelin During Cerebral Vasospasm after Experimental Subarachnoid Hemorrhage.

The Effect of Ecdysterone on Cerebral Vasospasm Following Experimental Subarachnoid Hemorrhage in Vitro and in Vivo

Potential Contribution of Matrix Metalloproteinase-9 (Mmp-9) to Cerebral Vasospasm after Experimental Subarachnoid Hemorrhage in Rats.

Treatment of cerebral vasospasm after subarachnoid hemorrhage--a review

Potential Contribution of Socc to Cerebral Vasospasm after Experimental Subarachnoid Hemorrhage in Rats